Group 1 - The presentation is led by Maxwell Skor, an equity analyst from Morgan Stanley, indicating a focus on financial analysis and investment insights [1] - The introduction of the Atea team suggests a collaborative effort to present the company's story and value proposition to the audience [1] - The mention of a disclosure highlights the importance of transparency and compliance in financial communications [1]

Group 1 - The presentation is led by Maxwell Skor, an equity analyst from Morgan Stanley, who introduces the Atea team to the audience [1] - The purpose of the introduction is to familiarize the audience with the Atea story, particularly for those who may not be well-acquainted with the company [1]

Atea Pharmaceuticals FY Conference Summary Company Overview - Atea Pharmaceuticals is a biotech company based in Boston focusing on a nucleoside platform for treating serious viral diseases, currently in phase 3 trials for its nucleoside analog, bemnifosbuvir, targeting hepatitis C [2][5] Core Scientific Rationale - Direct-acting antivirals for hepatitis C were approved about 10 years ago, with over 50 million people still infected globally, including 2.4 to 4 million in the U.S. [3] - The patient demographic has shifted to younger populations (30s and 40s), who are more medically complex, with approximately 80% on concomitant medications [3][4] - Atea's regimen aims to improve treatment adherence and minimize drug-drug interactions, aligning with WHO's goal to eradicate hepatitis C by 2030 [4] Clinical Trial Insights - Two ongoing phase 3 trials: CBYOND in North America and C4WRD globally, focusing on an eight-week treatment regimen for non-cirrhotic patients [18][19] - Phase 2 trial results showed a 98% cure rate overall, with 100% in non-cirrhotics, and 95% in non-compliant patients [11][12] - The regimen is designed to be potent, with no food effects and minimal drug-drug interactions, making it suitable for a broad patient population [6][12] Market Research Findings - A market study indicated that 76% of high-prescribing doctors are likely to prescribe bemnifosbuvir, with a preference for its potency and short treatment duration [8][10] - Doctors expressed a need for alternatives to current treatments, highlighting the appeal of Atea's regimen [9][10] Regulatory and Competitive Landscape - Atea's intellectual property extends to 2042, while competitors Epclusa and Mavyret have patent protection until 2034 [26][28] - The FDA has provided positive feedback on trial designs, emphasizing the importance of drug-drug interaction profiles and treatment duration [21][24] Financial Position and Capital Allocation - Atea reported a cash balance of $379 million, sufficient to fund the phase 3 program, estimated to cost around $200 million [36][41] - The company is focused on strategic partnerships post-phase 3 results to maximize asset value [42][43] Patient Demographics and Treatment Dynamics - The U.S. treatment landscape shows a static number of patients treated annually, with increasing incidence rates [30] - Government initiatives are underway to address hepatitis C treatment, including a proposed $10 billion bill targeting high-risk populations [31][32] Future Outlook - Upcoming milestones include phase 3 trial results expected in mid-2026, with additional presentations at major conferences [44] - Atea aims to leverage its unique position in the market to address unmet needs in hepatitis C treatment [46] Additional Considerations - Atea is exploring AI for early discovery activities while maintaining traditional methods [48] - The company believes its U.S. manufacturing capabilities provide a competitive advantage in the evolving regulatory landscape [50]

Company Overview - Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing oral antiviral therapies for serious viral diseases [3] - The company has developed a proprietary nucleos(t)ide prodrug platform aimed at treating single-stranded ribonucleic acid (ssRNA) viruses, which are a significant cause of serious viral infections [3] - Atea's lead program is in global Phase 3 development, focusing on a combination regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, specifically targeting Hepatitis C Virus (HCV) [3] Upcoming Events - Members of Atea's management team will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025, at 1:05 p.m. ET in New York [1] - A live webcast of the presentation will be available on the company's website, with an archived version accessible for at least 90 days following the event [2]

Core Viewpoint - Atea Pharmaceuticals reported its Q2 2025 results, highlighting improved cost controls and progress in its Phase 3 clinical program for hepatitis C, while facing risks from competition and lack of near-term revenue [1][4]. Financial Performance - The company reported a GAAP net loss per share of $0.44 for Q2 2025, better than the consensus estimate of a loss of $0.42 and the prior year's loss of $0.48 [1][2]. - No revenue was reported as the company remains in clinical development [1][7]. - Research and development expenses decreased by 6.9% to $32.3 million compared to Q2 2024, while general and administrative expenses fell by 25.4% to $9.1 million [2][5]. - Cash, cash equivalents, and marketable securities totaled $379.7 million at the end of Q2 2025, providing a multi-year runway at current spending rates [6][7]. Business Overview - Atea Pharmaceuticals focuses on developing therapies for hepatitis C, primarily through a combination therapy using bemnifosbuvir and ruzasvir [3][4]. - The company aims to address the unmet need in HCV treatment by offering shorter courses and improved safety compared to existing therapies [4]. Clinical Development - Atea's lead HCV regimen is advancing in clinical trials, with both global Phase 3 trials, C-BEYOND and C-FORWARD, progressing in enrollment [8]. - Phase 2 results showed a 98% sustained virologic response rate at 12 weeks post-treatment, indicating strong efficacy and safety [9][10]. Strategic Initiatives - The Board authorized a stock repurchase program for up to $25 million, with 4.6 million shares repurchased at an average price of $3.01 per share by the end of Q2 2025 [11]. - Atea engaged Evercore to explore strategic options, including potential mergers or partnerships, to enhance its market position [11]. Future Outlook - Management did not provide formal financial guidance for the remainder of fiscal 2025, reflecting uncertainty in clinical trials and commercial launch timelines [13][14]. - Investors will focus on updates regarding Phase 3 progress, pivotal data timelines, and outcomes from the strategic review process [14].

Financial Data and Key Metrics Changes - The company reported a cash, cash equivalents, and marketable securities balance of $379.7 million as of June 30, 2025, indicating a strong financial position to execute its Phase III HCV program [11] - Research and development (R&D) expenses decreased compared to the same period in 2024, primarily due to the conclusion of the Phase III SUNRISE trial [30] - General and administrative (G&A) expenses also decreased, attributed to lower stock-based compensation and payroll expenses [30] Business Line Data and Key Metrics Changes - The company is advancing its global Phase III HCV program, evaluating the regimen of Benifosbuvir and Ruzasvir, with patient enrollment on track [9][18] - The Phase II trial results showed a 98% sustained virologic response (SVR) rate in treatment-adherent patients after eight weeks, demonstrating the regimen's robust efficacy [16] Market Data and Key Metrics Changes - The global HCV market is approximately $3 billion in annual net sales, with a significant burden of untreated HCV disease representing a large untapped commercial opportunity [10][12] - In the U.S., there are between 2.4 and 4 million untreated individuals infected with HCV, highlighting the need for new therapies [12] Company Strategy and Development Direction - The company aims to develop a best-in-class regimen for HCV treatment, focusing on a new model of care called "test and treat" to enhance patient access and treatment outcomes [13][24] - The addition of a new independent director, Dr. Howard Berman, reflects the company's commitment to strengthening its leadership and strategic direction [8][32] Management's Comments on Operating Environment and Future Outlook - Management emphasized the ongoing high incidence of HCV infections, which outpaces the number of patients treated, underscoring the need for differentiated therapies [11][12] - The company anticipates top-line results from the C BEYOND trial in mid-2026 and from the C FORWARD trial in late 2026, indicating a clear timeline for future developments [10][18] Other Important Information - The company announced a stock repurchase program of up to $25 million, demonstrating its commitment to returning capital to shareholders while funding its clinical programs [8][32] - The Phase III trials will compare the new regimen to existing treatments, aiming to establish its superiority in efficacy and safety [19] Q&A Session Summary Question: Update on enrollment in Phase III C Beyond and C Forward trials - Enrollment is progressing on track, with C BEYOND moving faster due to quicker regulatory approvals in North America compared to C FORWARD [38][39] - Investigator enthusiasm is high, reflecting keen interest in the studies and the value proposition for patients [39]

Clinical Trials and Product Development - The company is currently conducting two Phase 3 clinical trials, C-Beyond and C-Forward, for its lead product candidate, bemnifosbuvir and ruzasvir, targeting HCV infection, with patient enrollment ongoing since April and June 2025 respectively [85][94]. - The Phase 2 clinical trial results showed a 98% sustained virologic response (SVR12) rate in treatment-adherent patients after eight weeks, demonstrating the regimen's high efficacy [97]. - The company expects to incur significant expenses as it advances its Phase 3 clinical development for the treatment of HCV [116]. - The company plans to continue using third-party service providers for clinical development and manufacturing [115]. Financial Position and Cash Flow - The company had $379.7 million in cash, cash equivalents, and marketable securities as of June 30, 2025, positioning it well to advance its current programs [104]. - As of June 30, 2025, the company had cash, cash equivalents, and marketable securities totaling $379.7 million [161]. - Net cash used in operating activities was $63.4 million for the six months ended June 30, 2025 [112]. - For the six months ended June 30, 2025, net cash used in operating activities was $63.4 million, primarily due to a net loss of $71.4 million [149]. - Net cash provided by investing activities for the six months ended June 30, 2025 was $100.9 million, consisting of sales and maturities of marketable securities of $324.3 million [151]. - The company incurred net cash used in financing activities of $14.4 million for the six months ended June 30, 2025, primarily due to stock repurchases [153]. Cost Management and Workforce - A workforce reduction of approximately 25% was implemented in Q1 2025, expected to result in cost savings of about $15.0 million through 2027 [104]. - The company reduced its workforce by approximately 25% in Q1 2025, expecting cost savings of about $15 million through 2027 [112]. - Research and development expenses decreased by $30.4 million from $92.3 million for the six months ended June 30, 2024, to $61.9 million for the same period in 2025 [134]. - Total operating expenses for the six months ended June 30, 2025, were $80.4 million, down from $116.7 million in 2024 [133]. Revenue Generation and Future Outlook - The company has not generated any product revenue since inception and does not anticipate doing so in the foreseeable future, relying on financing for operations [107]. - The company does not anticipate generating any revenue from product sales for the foreseeable future [114]. - The company has not generated any product revenue to date and does not expect to until regulatory approval and commercialization of product candidates occur [141]. - The company anticipates needing to raise substantial additional capital to fund operations and development, with requirements depending on various factors [143]. - The company may face challenges in raising adequate funding on acceptable terms, which could negatively impact its financial condition [146]. - Market volatility and macroeconomic trends may significantly impact the availability of funding sources and terms [147]. Strategic Partnerships and Milestones - The first milestone payment of $5.0 million under the Merck License Agreement was recognized as a research and development expense upon enrolling the first patient in the C-Beyond trial [111]. - The next potential milestone payment of $10.0 million is anticipated upon FDA acceptance of a new drug application for the regimen of bemnifosbuvir and ruzasvir [111]. - The company is exploring strategic alternatives, including partnerships and acquisitions, to enhance stockholder value, with no assurance of specific outcomes [108]. Stock Repurchase Activity - The company repurchased 4,619,597 shares for approximately $14.1 million during the three months ended June 30, 2025, with $11.1 million remaining authorized for future repurchases [106]. - The company repurchased 4,619,597 shares of common stock for approximately $14.1 million during the three months ended June 30, 2025, with $11.1 million remaining for future repurchases [142].

HCV Program & Clinical Trials - Phase 3 trial C-BEYOND (US/Canada) and C-FORWARD (Outside North America) initiated with first patient dosed in April and June 2025 respectively[12] - Phase 2 results showed 98% SVR12 in treatment adherent patients and 95% SVR12 regardless of adherence[28,29] - Phase 2 results also demonstrated 99% SVR12 in non-cirrhotic treatment adherent patients across genotypes and 97% SVR12 regardless of adherence[31,32] Market Opportunity & KOL Insights - Untreated HCV infections in the US range from 24 million to 4 million, with over 170,000 newly reported annual infections exceeding annual cures[16] - The US HCV market is estimated at ~$15 billion in 2024, with a potential market opportunity exceeding $20 billion[19] - KOL panel highlighted the need for simpler, shorter HCV treatments with fewer drug-drug interactions to improve patient adherence and expand the test-and-treat model[49] Financial Status - Cash, cash equivalents, and marketable securities totaled $3797 million as of June 30, 2025, providing a cash runway through 2027[13] - The company authorized and initiated a repurchase of up to $25 million of its common stock in April 2025, with 46 million shares repurchased as of June 30, 2025[9,67] - Net loss for the second quarter of 2025 was $37161 million, compared to $40522 million for the same period in 2024[64]

Executive Summary & Business Update Atea Pharmaceuticals reported Q2 2025 financial results and business updates, emphasizing global Phase 3 HCV program advancements and recent scientific data [Second Quarter 2025 Highlights](index=1&type=section&id=Second%20Quarter%202025%20Highlights) Atea Pharmaceuticals reported Q2 2025 financial results and a business update, highlighting significant progress in its global Phase 3 HCV treatment program - Atea Pharmaceuticals reported financial results for the second quarter ended June 30, 2025, and provided a business update[2](index=2&type=chunk) [HCV Phase 3 Development Program](index=1&type=section&id=HCV%20Phase%203%20Development%20Program) Atea is advancing its global Phase 3 program for bemnifosbuvir/ruzasvir HCV treatment, with enrollment on track, supported by strong Phase 2 efficacy (**98% SVR12**) and favorable PK/DDI profiles [C-BEYOND and C-FORWARD Trials Overview](index=1&type=section&id=C-BEYOND%20and%20C-FORWARD%20Trials%20Overview) Atea's global Phase 3 HCV program (C-BEYOND, C-FORWARD) is on track, evaluating bemnifosbuvir/ruzasvir against standard therapy, with SVR12 as the primary endpoint - Atea's combination regimen of bemnifosbuvir/ruzasvir is being evaluated in a global Phase 3 development program for HCV, comprising two trials: C-BEYOND (US/Canada) and C-FORWARD (outside North America)[3](index=3&type=chunk)[6](index=6&type=chunk) - Global patient enrollment is on track in both C-BEYOND and C-FORWARD trials, which were initiated in April and June 2025, respectively[4](index=4&type=chunk)[6](index=6&type=chunk) - Each Phase 3 trial enrolls approximately 880 treatment-naïve patients and compares bemnifosbuvir/ruzasvir (8 or 12 weeks) to sofosbuvir/velpatasvir (12 weeks)[7](index=7&type=chunk) - The primary endpoint for each trial is HCV RNA < lower limit of quantitation (LLOQ) at 24 weeks from the start of treatment, encompassing SVR12[8](index=8&type=chunk) [EASL Congress 2025 Presentations](index=2&type=section&id=EASL%20Congress%202025%20Presentations) EASL 2025 presentations highlighted bemnifosbuvir/ruzasvir's robust Phase 2 efficacy (**98% SVR12**) and favorable pharmacokinetic profiles for hepatic/renal impairment and drug interactions - Phase 2 efficacy results for bemnifosbuvir/ruzasvir showed a robust **98% SVR12** in the 'Per-Protocol Treatment-Adherent Population' (n=215)[9](index=9&type=chunk) - Phase 1 pharmacokinetic results support the use of bemnifosbuvir without dose adjustment in patients with hepatic impairment[9](index=9&type=chunk) - Phase 1 drug-drug interaction results demonstrated no clinically significant pharmacokinetic changes when co-administered with the standard HIV regimen bictegravir/emtricitabine/tenofovir alafenamide (B/FTC/TAF)[9](index=9&type=chunk) - Phase 1 renal impairment results suggest bemnifosbuvir may be used without dose adjustment in patients with renal dysfunction, including those undergoing dialysis[9](index=9&type=chunk) [HCV Key Opinion Leader (KOL) Discussion Panel Event](index=3&type=section&id=HCV%20Key%20Opinion%20Leader%20(KOL)%20Discussion%20Panel%20Event) Atea hosted a virtual KOL event on May 14, 2025, where experts discussed HCV challenges, Phase 2 results, and commercial opportunities for optimized HCV therapy - Atea hosted a virtual KOL investor event on May 14, 2025, featuring six HCV experts to discuss current challenges, Atea's Phase 2 results, and the commercial market opportunity for an optimized HCV therapy[10](index=10&type=chunk) Financial Results Atea's Q2 2025 financial results indicate decreased cash, reduced R&D and G&A expenses, and an improved net loss year-over-year [Key Financial Metrics](index=3&type=section&id=Key%20Financial%20Metrics) Atea's cash, cash equivalents, and marketable securities decreased to **$379.7 million** by June 30, 2025, with R&D and G&A expenses also decreasing year-over-year **Cash, Cash Equivalents and Marketable Securities:** | Date | Amount (Millions) | | :--- | :--- | | June 30, 2025 | $379.7 | | December 31, 2024 | $454.7 | **Research and Development Expenses (Three Months Ended June 30):** | Year | Amount (Millions) | Change (YoY) | | :--- | :--- | :--- | | 2025 | $32.3 | -$2.4 | | 2024 | $34.7 | | *Primarily driven by substantially lower COVID-19 external spend and decreased internal expenses, offset by increased HCV Phase 3 program spend.* **General and Administrative Expenses (Three Months Ended June 30):** | Year | Amount (Millions) | Change (YoY) | | :--- | :--- | :--- | | 2025 | $9.1 | -$3.2 | | 2024 | $12.2 | | *Primarily related to lower stock-based compensation expense, partially offset by increased professional fees.* **Interest Income and Other, Net (Three Months Ended June 30):** | Year | Amount (Millions) | Change (YoY) | | :--- | :--- | :--- | | 2025 | $4.4 | -$2.2 | | 2024 | $6.6 | | *Primarily due to lower investment balances.* [Condensed Consolidated Statement of Operations and Comprehensive Loss](index=4&type=section&id=Condensed%20Consolidated%20Statement%20of%20Operations%20and%20Comprehensive%20Loss) For Q2 2025, Atea reported a net loss of **$37.161 million**, an improvement from **$40.522 million** in 2024, with total operating expenses decreasing year-over-year **Condensed Consolidated Statement of Operations and Comprehensive Loss (Unaudited, in thousands):** | Metric | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :-------------------------------- | :--------------------------------- | :--------------------------------- | :-------------------------------- | :-------------------------------- | | Research and development | $32,275 | $34,696 | $61,859 | $92,271 | | General and administrative | $9,070 | $12,220 | $18,527 | $24,451 | | Total operating expenses | $41,345 | $46,916 | $80,386 | $116,722 | | Loss from operations | $(41,345) | $(46,916) | $(80,386) | $(116,722) | | Interest income and other, net | $4,391 | $6,637 | $9,363 | $13,505 | | Loss before income taxes | $(36,954) | $(40,279) | $(71,023) | $(103,217) | | Income tax expense | $(207) | $(243) | $(410) | $(474) | | Net loss | $(37,161) | $(40,522) | $(71,433) | $(103,691) | | Net loss per share - basic and diluted | $(0.44) | $(0.48) | $(0.85) | $(1.23) | [Selected Condensed Consolidated Balance Sheet Data](index=4&type=section&id=Selected%20Condensed%20Consolidated%20Balance%20Sheet%20Data) As of June 30, 2025, Atea's total assets stood at **$391.605 million**, a decrease from **$464.668 million** at December 31, 2024, with total stockholder's equity also declining **Selected Condensed Consolidated Balance Sheet Data (Unaudited, in thousands):** | Metric | June 30, 2025 | December 31, 2024 | | :--------------------------------- | :---------------- | :------------------ | | Cash, cash equivalents and marketable securities | $379,713 | $454,721 | | Working capital | $365,485 | $443,752 | | Total assets | $391,605 | $464,668 | | Total liabilities | $27,189 | $25,801 | | Total stockholder's equity | $364,416 | $438,867 | Business and Organizational Updates Atea strengthened its Board and initiated a stock repurchase program, while actively exploring strategic alternatives to enhance shareholder value [Corporate Governance and Capital Allocation](index=3&type=section&id=Corporate%20Governance%20and%20Capital%20Allocation) Atea strengthened its Board with a new appointment and initiated a **$25 million** common stock repurchase program, demonstrating commitment to shareholder returns - Dr. Howard H. Berman was appointed to Atea's Board of Directors in June 2025, bringing over 20 years of life science industry experience[14](index=14&type=chunk) - In April 2025, Atea authorized the repurchase of up to **$25 million** of its common stock[14](index=14&type=chunk) - As of June 30, 2025, the Company had repurchased **4,619,597 shares** of common stock at an average purchase price of **$3.01 per share**[14](index=14&type=chunk) [Strategic Alternatives Review](index=3&type=section&id=Strategic%20Alternatives%20Review) Atea is actively exploring a broad range of strategic alternatives to maximize shareholder value, including potential partnerships, acquisitions, or asset sales, with Evercore assisting - Atea is evaluating all options to maximize shareholder value, including strategic partnerships, acquisition, merger, or other business combination, and sale of assets[14](index=14&type=chunk) - The Company has engaged Evercore to assist in the strategic alternatives review process[14](index=14&type=chunk) Company and Disease Background This section outlines HCV as a global health burden and introduces Atea Pharmaceuticals' focus on developing oral antiviral therapies using its proprietary nucleos(t)ide prodrug platform [About HCV](index=5&type=section&id=About%20HCV) HCV remains a significant global health burden, with an estimated **50 million people** chronically infected worldwide and approximately **one million new infections** annually - HCV is a blood-borne, single-stranded RNA virus, a leading cause of chronic liver disease and liver transplants, causing approximately **240,000 deaths** annually[22](index=22&type=chunk) - An estimated **50 million people** worldwide are chronically infected with HCV, with approximately **one million new infections** each year[22](index=22&type=chunk) - In the US, between **2.4 and 4.0 million people** are estimated to have HCV, with annual new infections outpacing treatment rates[22](index=22&type=chunk) - Chronic HCV infection is the leading cause of liver cancer in the US, Europe, and Japan[22](index=22&type=chunk) [About Atea Pharmaceuticals](index=5&type=section&id=About%20Atea%20Pharmaceuticals) Atea Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing oral antiviral therapies for serious viral infections - Atea is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing oral antiviral therapies for serious viral infections[23](index=23&type=chunk) - The company utilizes a proprietary nucleos(t)ide prodrug platform to develop novel product candidates for single-stranded ribonucleic acid (ssRNA) viruses[23](index=23&type=chunk) - Atea's lead program and current focus is the development of the combination of bemnifosbuvir and ruzasvir to treat HCV[23](index=23&type=chunk) Legal & Contact Information This section outlines standard forward-looking statements, emphasizing inherent uncertainties and risk factors, and provides contact information for investor and corporate communications [Forward-Looking Statements](index=5&type=section&id=Forward-Looking%20Statements) This section contains standard forward-looking statements, based on current expectations but inherently uncertain, with actual results potentially differing due to various factors - The press release includes 'forward-looking statements' as defined by the Private Securities Litigation Reform Act of 1995[24](index=24&type=chunk) - These statements are based on Atea's current expectations and assumptions, but are inherently uncertain, and actual results could differ materially[24](index=24&type=chunk) - Important factors that could cause actual results to differ include uncertainties in drug discovery and development, regulatory processes, unexpected safety/efficacy data, clinical trial delays, reliance on third parties, competition, and the timeline/outcome of the strategic alternatives review[24](index=24&type=chunk)[25](index=25&type=chunk) [Contacts](index=6&type=section&id=Contacts) This section provides contact information for investor relations and corporate communications - Contact information is provided for Jonae Barnes, SVP, Investor Relations and Corporate Communications, and Joyce Allaire of LifeSci Advisors[26](index=26&type=chunk)

Core Viewpoint - Atea Pharmaceuticals, Inc. will host a live conference call on August 7, 2025, to report its financial results for Q2 2025 and provide a business update [1]. Company Overview - Atea Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing oral antiviral therapies for serious viral diseases [3]. - The company utilizes a proprietary nucleos(t)ide prodrug platform to develop novel product candidates targeting single-stranded RNA viruses [3]. - Atea's lead program focuses on the combination of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, aimed at treating Hepatitis C Virus (HCV) [3]. Conference Call Details - The conference call will take place at 4:30 p.m. ET on August 7, 2025, and will be accessible via telephone or through an audio webcast on the company's website [2]. - Participants can register for the call and access an archive of the audio webcast approximately two hours after the event, which will remain available for at least 90 days [2].